228 related articles for article (PubMed ID: 27696457)
1. Glyoxalase 2 Is Involved in Human Prostate Cancer Progression as Part of a Mechanism Driven By PTEN/PI3K/AKT/mTOR Signaling With Involvement of PKM2 and ERα.
Talesa VN; Ferri I; Bellezza G; Love HD; Sidoni A; Antognelli C
Prostate; 2017 Feb; 77(2):196-210. PubMed ID: 27696457
[TBL] [Abstract][Full Text] [Related]
2. Glyoxalase 2 drives tumorigenesis in human prostate cells in a mechanism involving androgen receptor and p53-p21 axis.
Antognelli C; Ferri I; Bellezza G; Siccu P; Love HD; Talesa VN; Sidoni A
Mol Carcinog; 2017 Sep; 56(9):2112-2126. PubMed ID: 28470764
[TBL] [Abstract][Full Text] [Related]
3. GOLM1 promotes prostate cancer progression through activating PI3K-AKT-mTOR signaling.
Yan G; Ru Y; Wu K; Yan F; Wang Q; Wang J; Pan T; Zhang M; Han H; Li X; Zou L
Prostate; 2018 Feb; 78(3):166-177. PubMed ID: 29181846
[TBL] [Abstract][Full Text] [Related]
4. Glyoxalases in Urological Malignancies.
Antognelli C; Talesa VN
Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29385039
[TBL] [Abstract][Full Text] [Related]
5. Depletion of SAG/RBX2 E3 ubiquitin ligase suppresses prostate tumorigenesis via inactivation of the PI3K/AKT/mTOR axis.
Tan M; Xu J; Siddiqui J; Feng F; Sun Y
Mol Cancer; 2016 Dec; 15(1):81. PubMed ID: 27955654
[TBL] [Abstract][Full Text] [Related]
6. AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis.
Li N; Xue W; Yuan H; Dong B; Ding Y; Liu Y; Jiang M; Kan S; Sun T; Ren J; Pan Q; Li X; Zhang P; Hu G; Wang Y; Wang X; Li Q; Qin J
J Clin Invest; 2017 Apr; 127(4):1284-1302. PubMed ID: 28319045
[TBL] [Abstract][Full Text] [Related]
7. Role of PI3K-AKT-mTOR Pathway as a Pro-Survival Signaling and Resistance-Mediating Mechanism to Therapy of Prostate Cancer.
Pungsrinont T; Kallenbach J; Baniahmad A
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681745
[TBL] [Abstract][Full Text] [Related]
8. Glyoxalase 1 sustains the metastatic phenotype of prostate cancer cells via EMT control.
Antognelli C; Cecchetti R; Riuzzi F; Peirce MJ; Talesa VN
J Cell Mol Med; 2018 May; 22(5):2865-2883. PubMed ID: 29504694
[TBL] [Abstract][Full Text] [Related]
9. MiR-146b inhibits autophagy in prostate cancer by targeting the PTEN/Akt/mTOR signaling pathway.
Gao S; Zhao Z; Wu R; Wu L; Tian X; Zhang Z
Aging (Albany NY); 2018 Aug; 10(8):2113-2121. PubMed ID: 30153654
[TBL] [Abstract][Full Text] [Related]
10. Role of PI3K, mTOR and Akt2 signalling in hepatic tumorigenesis via the control of PKM2 expression.
Nemazanyy I; Espeillac C; Pende M; Panasyuk G
Biochem Soc Trans; 2013 Aug; 41(4):917-22. PubMed ID: 23863156
[TBL] [Abstract][Full Text] [Related]
11. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
[TBL] [Abstract][Full Text] [Related]
12. Progesterone Receptor Expression in the Benign Prostatic Hyperplasia and Prostate Cancer Tissues, Relation with Transcription, Growth Factors, Hormone Reception and Components of the AKT/mTOR Signaling Pathway.
Spirina LV; Kovaleva IV; Usynin EA; Goorbunov AK; Kondakova IV
Asian Pac J Cancer Prev; 2020 Feb; 21(2):423-429. PubMed ID: 32102520
[TBL] [Abstract][Full Text] [Related]
13. Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion.
Shukla S; Maclennan GT; Hartman DJ; Fu P; Resnick MI; Gupta S
Int J Cancer; 2007 Oct; 121(7):1424-32. PubMed ID: 17551921
[TBL] [Abstract][Full Text] [Related]
14. Deregulated PTEN/PI3K/AKT/mTOR signaling in prostate cancer: Still a potential druggable target?
Braglia L; Zavatti M; Vinceti M; Martelli AM; Marmiroli S
Biochim Biophys Acta Mol Cell Res; 2020 Sep; 1867(9):118731. PubMed ID: 32360668
[TBL] [Abstract][Full Text] [Related]
15. RUNX2 overexpression and PTEN haploinsufficiency cooperate to promote CXCR7 expression and cellular trafficking, AKT hyperactivation and prostate tumorigenesis.
Bai Y; Yang Y; Yan Y; Zhong J; Blee AM; Pan Y; Ma T; Karnes RJ; Jimenez R; Xu W; Huang H
Theranostics; 2019; 9(12):3459-3475. PubMed ID: 31281490
[No Abstract] [Full Text] [Related]
16. Association of mTOR Pathway Markers and Clinical Outcomes in Patients with Intermediate-/High-risk Prostate Cancer: Long-Term Analysis.
Barata PC; Magi-Galluzzi C; Gupta R; Dreicer R; Klein EA; Garcia JA
Clin Genitourin Cancer; 2019 Oct; 17(5):366-372. PubMed ID: 31262501
[TBL] [Abstract][Full Text] [Related]
17. Apoptosis of human prostate cancer cells induced by marine actinomycin X2 through the mTOR pathway compounded by MiRNA144.
Liu J; Xie S; Wu Y; Xu M; Ao C; Wang W; Zeng Q; Hu W; Li M
Anticancer Drugs; 2016 Mar; 27(3):156-63. PubMed ID: 26645890
[TBL] [Abstract][Full Text] [Related]
18. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
[TBL] [Abstract][Full Text] [Related]
19. Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway.
Ni J; Cozzi P; Hao J; Beretov J; Chang L; Duan W; Shigdar S; Delprado W; Graham P; Bucci J; Kearsley J; Li Y
Int J Biochem Cell Biol; 2013 Dec; 45(12):2736-48. PubMed ID: 24076216
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Wnt signaling downregulates Akt activity and induces chemosensitivity in PTEN-mutated prostate cancer cells.
Ohigashi T; Mizuno R; Nakashima J; Marumo K; Murai M
Prostate; 2005 Jan; 62(1):61-8. PubMed ID: 15389810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
